在第一线易布鲁替尼治疗高风险CLL/SLL患者的现实生存结果
John N Allan1, Tao Ran2, Zhijie Ding3
1Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, United States.
Blood advances
|May 12, 2025
概括
慢性淋巴细胞白血病 (CLL) /小淋巴细胞淋巴瘤 (SLL) 的高风险细胞遗传特征对接受一线易布鲁替尼的患者的整体存活率没有影响. 现实世界的数据显示,无论遗传标记如何,结果都相似.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 遗传学 遗传学 是一个
背景情况:
- 慢性淋巴细胞白血病 (CLL) /小淋巴细胞淋巴瘤 (SLL) 可以呈现高风险细胞遗传特征 (del(17p),del(11q),未变异的IGHV).
- 这些特征通常与较差的预后和治疗结果有关.
研究的目的:
- 为了评估CLL/SLL患者的现实整体存活率 (rwOS),这些患者接受了第一线IBRUTINIB治疗.
- 为了比较具有和没有高风险细胞遗传特征的患者之间的rwOS.
主要方法:
- 追溯性队列研究,使用大型的非标识电子健康记录数据库.
- 包括1,242名接受一线IBRUTINIB治疗的患者.
- 使用治疗权重的逆概率 (IPTW) 来调整基线特征.
主要成果:
- 在高风险和非高风险的CLL/SLL患者之间没有观察到中位数rwOS的显著差异 (HR:1.09;95%CI:0.791.51).
- 敏感性分析,包括排除del{11q}或专注于医疗保险患者的敏感性分析,也得出了类似的结果.
- 在任何一个队列中都没有达到中位数rwOS,这表明两组的生存时间都延长了.
结论:
- 第一线易布鲁替尼治疗表明,CLL/SLL患者的整体存活率与现实世界相当,不论高风险的细胞遗传特征如何.
- 这些发现表明,易布鲁替尼可能会克服CLL/SLL遗传异常的负面预后影响.
- 现实数据支持ibrutinib在广泛的CLL/SLL患者群体中的疗效.
更多相关视频
14:04Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
15.2K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
相关概念视频
01:20Actuarial Approach
41
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
41
01:21Cancer Survival Analysis
301
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
301